Definium Therapeutics shares climb as synthetic LSD treatment shows superior efficacy in Phase 2 anxiety trials, marking another milestone for the biotech firm.
Definium Therapeutics reported positive Phase 2 results for its synthetic LSD anxiety treatment, showing significant improvement over placebo, driving shares higher.
Definium Therapeutics shares surged following positive Phase 2 clinical trial results for its synthetic LSD treatment. Patients receiving the drug demonstrated a 9.8-point improvement on the Hamilton Anxiety Rating Scale, significantly outperforming the 4.7-point gain observed in the placebo group.
The trial showed that patients treated with synthetic LSD experienced a 9.8-point improvement on the Hamilton Anxiety Rating Scale after 12 weeks, compared to a 4.7-point improvement in the placebo group.